Sanara Medtech earnings missed by $0.20, revenue fell short of estimates

Sanara Medtech (SMTI) reported Q3 EPS of -$0.16, missing estimates by $0.20, with revenue at $28.43M, below the $29.95M consensus. Shares closed at $32.54, down 4.71% over 3 months but up 65.94% year-over-year. InvestingPro rates its financial health as 'good performance.'

Original reporting
Published Nov 12, 2026, 11:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SMTI
Bearish
high confidence
Mentioned
$SMTI
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SMTIBearishMed
01

Why it matters

The earnings miss is a fresh, primary disclosure that may drive short‑term downside.

02

Market read

Earnings miss for a micro‑cap; limited broader market effect but actionable for traders holding or shorting SMTI.

03

What to watch

Potential upcoming pipeline milestones or partnership announcements not covered in this release.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

Sanara Medtech (SMTI) is a micro‑cap medical technology company listed on NASDAQ. The article reports its latest quarterly earnings.

Company-level read

Ticker impact

$SMTIBearishHigh confidence
Context

Q3 EPS of -$0.16 missed the $0.04 estimate and revenue of $28.43M fell short of the $29.95M consensus.

Expected impact

downward pressure as investors price in the miss

Evidence & confidence

Both EPS and revenue came in below expectations, a clear negative catalyst for a micro‑cap stock.

Market effects

Limited impact on the broader biotech sector; mainly a micro‑cap specific reaction.

Primarily U.S. over‑the‑counter market activity.

Low global relevance due to the company's small size.

Counterpoint

If the miss is viewed as a temporary setback, the stock could be a cheap entry point for risk‑tolerant investors.

Key entities

  • Sanara Medtech

    NASDAQ‑listed medical technology firm.

Related articles

$SMTIMed

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

$SMTIMedAI 8/10

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

$SMTIMedAI 8/10

Sanara MedTech Inc., a Texas corporation, entered into an Agreement and Plan of Merger with MiMedx Group, Inc., a Florida corporation, and Mustang Merger…

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, Sanara MedTech Inc., a Texas corporation (the “Company” or “Sanara”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MiMedx Group, Inc., a Florida corporation (“MiMedx”), and Mustang Merger Sub, Inc., a